Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose.
about
Pathogenesis and management of Kawasaki diseaseSalicylate for the treatment of Kawasaki disease in childrenKawasaki syndromeAssociated symptoms of kawasaki diseaseKawasaki diseaseAudit of therapeutic interventions in inpatient children using two scores: are they evidence-based in developing countries?Therapeutic advances in the treatment of vasculitisKawasaki disease: an evidence based approach to diagnosis, treatment, and proposals for future researchComparison of high-dose and low-dose aspirin plus intravenous immunoglobulin in the treatment of Kawasaki syndromeKawasaki disease: diagnosis, management and cardiac sequelaeMeta-analysis of the results of intravenous gamma globulin treatment of coronary artery lesions in Kawasaki disease.Kawasaki disease: laboratory findings and an immunopathogenesis on the premise of a "protein homeostasis system".Steroid pulse therapy for Kawasaki disease unresponsive to additional immunoglobulin therapyAugmented TLR2 expression on monocytes in both human Kawasaki disease and a mouse model of coronary arteritisIntravenous immunoglobulin in neurological disease: a specialist review.Comparative effectiveness of intravenous immunoglobulin for children with Kawasaki disease: a nationwide cohort study.Kawasaki syndrome: an intriguing disease with numerous unsolved dilemmasEpidemiologic survey of Kawasaki disease in Jilin from 1999 through 2008.Plasma follistatin-like protein 1 is elevated in Kawasaki disease and may predict coronary artery aneurysm formationIs high-dose aspirin necessary in the acute phase of kawasaki disease?Arterial thrombosis in children.Epidemiologic survey of Kawasaki disease in Inner Mongolia, China, between 2001 and 2013.Extracardial Vasculopathy After Kawasaki Disease: A Long-Term Follow-up Study.Kawasaki disease at British Columbia's Children's Hospital.Associated symptoms in the ten days before diagnosis of Kawasaki disease.Coronary Artery Aneurysms in Kawasaki Disease: Risk Factors for Progressive Disease and Adverse Cardiac Events in the US Population.Prediction of responsiveness or non-responsiveness to treatment of acute Kawasaki disease using 1 gram per kilogram of immunoglobulin--an effective and cost-saving schedule of therapy.Management of Kawasaki disease.Pharmacotherapy of vasculitis.Kawasaki disease in Mongolia: results from 2 nationwide retrospective surveys, 1996-2008.Management of acute and refractory Kawasaki disease.Kawasaki disease: insights into pathogenesis and approaches to treatment.Overview of Pharmacological Treatment Options for Pediatric Patients with Refractory Kawasaki DiseaseIntravenous immunoglobulin-related hemolysis in patients treated for Kawasaki disease.Kawasaki disease and coronary artery aneurysms: from childhood to adulthood.Carotid intima-media thickness in children with Kawasaki disease.Dissecting Kawasaki disease: a state-of-the-art review.Cardiovascular involvement in Kawaski Disease.Inhibition of matrix metalloproteinase-9 activity improves coronary outcome in an animal model of Kawasaki disease.Kawasaki disease: Medical therapies.
P2860
Q22305933-3B16CDA3-4251-4526-8DBC-A71CA809188CQ24243818-BA1075A0-43AA-4EDD-81C7-D47DFF268C5BQ24550744-A4357B22-646A-4DF1-9C2F-8C0DF1FA0D3EQ24620972-A68CBDCB-D9AA-4A70-9EC3-E34C87B672F5Q24654153-AB396DAF-684B-4426-9663-90B54684F7A4Q24800327-F534A7AF-6685-42B8-B9B4-BA2072410583Q26750499-C9BC09B1-B903-4C73-9C63-3F058B15CAF1Q28192643-D28B3892-5AB0-4EBA-BF23-25C4E0C3FF32Q28194044-339976C9-1C50-46C6-8C45-03172F6378F4Q28210070-6911A2E4-67BB-405F-85DF-106897BD72D7Q33265368-A1891D05-8785-4164-8E4A-FCD0C51D5F9EQ34253124-13E69A75-A46A-4BC2-A686-8908DEC396DEQ34302870-AE5B4AB5-7B77-4FDC-B4C3-8A21D3723A32Q34318350-E462B837-A8AA-4422-8E2B-8BCF4813CA9EQ34574581-AC0D4F1F-61FA-4BBF-82B9-C55A51C49E88Q34708567-F4370387-F299-4EA9-9685-7259F7447E44Q35184950-34E072E1-AF02-4BAB-ABEE-C173B5DB62B0Q35691096-D2C9FFED-4E09-47C7-9219-F6CAA5CEF9A8Q35951695-0D44E52F-4474-481B-8758-63BDFF75ACEAQ36774715-DB064459-3971-4540-8F46-19071FC44287Q37104883-9CFD349A-8F8D-4033-B256-4D26B5DFE4E3Q37108769-FFB2E038-C048-4C27-B25E-C85ABB024C7DQ37240673-C10DB381-8438-4EF9-B285-8B3187623499Q37289341-F3221033-7388-4D56-9FE2-28239FEC7EDBQ37349659-CD7805AF-444C-42AF-BDC0-B3B5C3F0F113Q37364378-290ACB88-ACEB-4398-A2D8-3000DED435F2Q37409546-16D4173D-883F-43A4-A7CB-8B18A792BCC6Q37465500-7AE8BF2E-BA49-4CB2-9006-8C53FBE00A8FQ37483910-BFEA3253-6FC2-4A2A-80FF-3291C5DADA7DQ37506277-FA0CF050-28B5-487C-8071-856A4C94CD4BQ38063969-1F1D3368-AF7A-4DAD-B55C-EE4C3EF39A26Q38439648-25905C83-4011-41E6-98BC-8A76DCCABC7FQ38546497-DB982AC2-7466-4AC2-9F3C-A31786E44819Q38547199-FB83BF05-C328-4DEF-9053-569D8EE91D4FQ38638912-466DF90D-4D99-4D7A-A7E9-7FADA590E426Q39370548-EB0E76C2-BDE0-4FBA-BBAA-CBA0297A633EQ39401720-44025131-7AA0-4052-883E-3A8EC47584F5Q39654279-2112B0CA-49A3-45B6-8ACF-43D1342CB82FQ39825109-D0C44CD9-ACC9-4E63-9152-65ED25226045Q40054079-2C68CE31-0E38-4B60-8124-30860FAD10BB
P2860
Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose.
description
1997 nî lūn-bûn
@nan
1997 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
Prevalence of coronary artery ...... ndependent of salicylate dose.
@ast
Prevalence of coronary artery ...... ndependent of salicylate dose.
@en
Prevalence of coronary artery ...... ndependent of salicylate dose.
@nl
type
label
Prevalence of coronary artery ...... ndependent of salicylate dose.
@ast
Prevalence of coronary artery ...... ndependent of salicylate dose.
@en
Prevalence of coronary artery ...... ndependent of salicylate dose.
@nl
prefLabel
Prevalence of coronary artery ...... ndependent of salicylate dose.
@ast
Prevalence of coronary artery ...... ndependent of salicylate dose.
@en
Prevalence of coronary artery ...... ndependent of salicylate dose.
@nl
P1476
Prevalence of coronary artery ...... ndependent of salicylate dose.
@en
P2093
P304
P356
10.1016/S0022-3476(97)70038-6
P407
P577
1997-12-01T00:00:00Z